A Bristol Meyers Squibb executive was indicted for making a secret deal with a Canadian drug manufacturer that they wouldn’t make a generic version of Apotex, a competing drug to Plavix, if the Canucks didn’t make a generic version of Plavix. Under federal law, such anti-competitive agreements need to be submitted to the FTC. [NYT]
By consumerist.com April 24, 2008
More From Consumerist
- Why Does A Tube Of Cold Sore Cream Cost $2,500?
- Appeals Court Blocks Utah Law That Would Have Banned Price-Fixing On Contact Lenses
- We Live In A World Where Your Insurer Doesn’t Care That It Charges Two Prices For One Drug
- FTC Challenges Sysco Acquisition Of US Foods
- Competitor Gas-X Objects To DulcoGas ‘Maximum Strength’ Label